Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) EBITDA (2016 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 12 years of EBITDA data on record, last reported at -$120.3 million in Q4 2025.

  • For Q4 2025, EBITDA fell 49.1% year-over-year to -$120.3 million; the TTM value through Dec 2025 reached -$342.1 million, down 26.58%, while the annual FY2025 figure was -$342.1 million, 26.58% down from the prior year.
  • EBITDA reached -$120.3 million in Q4 2025 per VRDN's latest filing, down from -$34.3 million in the prior quarter.
  • Across five years, EBITDA topped out at -$14.0 million in Q3 2021 and bottomed at -$120.3 million in Q4 2025.
  • Average EBITDA over 5 years is -$53.0 million, with a median of -$48.4 million recorded in 2023.
  • The widest YoY moves for EBITDA: up 67.93% in 2021, down 179.02% in 2021.
  • A 5-year view of EBITDA shows it stood at -$29.1 million in 2021, then crashed by 55.45% to -$45.2 million in 2022, then crashed by 46.92% to -$66.5 million in 2023, then fell by 21.38% to -$80.7 million in 2024, then crashed by 49.1% to -$120.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$120.3 million in Q4 2025, -$34.3 million in Q3 2025, and -$100.9 million in Q2 2025.